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Abstract
Introduction: We hypothesised that breast cancer risk for relatives of women with early-onset breast cancer could
be predicted by tumour morphological features.
Methods: We studied female first-degree relatives of a population-based sample of 452 index cases with a first
primary invasive breast cancer diagnosed before the age of 40 years. For the index cases, a standardised tumour
morphology review had been conducted for all; estrogen (ER) and progesterone receptor (PR) status was available
for 401 (89%), and 77 (17%) had a high-risk mutation in a breast cancer susceptibility gene or methylation of the
BRCA1 promoter region in peripheral blood DNA. We calculated standardised incidence ratios (SIR) by comparing
the number of mothers and sisters with breast cancer with the number expected based on Australian incidence
rates specific for age and year of birth.
Results: Using Cox proportional hazards modelling, absence of extensive sclerosis, extensive intraductal carcinoma,
absence of acinar and glandular growth patterns, and the presence of trabecular and lobular growth patterns were
independent predictors with between a 1.8- and 3.1-fold increased risk for relatives (all P <0.02). Excluding index
cases with known genetic predisposition or BRCA1 promoter methylation, absence of extensive sclerosis,
circumscribed growth, extensive intraductal carcinoma and lobular growth pattern were independent predictors
with between a 2.0- and 3.3-fold increased risk for relatives (all P <0.02). Relatives of the 128 (34%) index cases with
none of these four features were at population risk (SIR = 1.03, 95% CI = 0.57 to 1.85) while relatives of the 37
(10%) index cases with two or more features were at high risk (SIR = 5.18, 95% CI = 3.22 to 8.33).
Conclusions: This wide variation in risks for relatives based on tumour characteristics could be of clinical value,
help discover new breast cancer susceptibility genes and be an advance on the current clinical practice of using
ER and PR as pathology-based predictors of familial and possibly genetic risks.
Introduction
While information about breast tumour morphology is
used to make important decisions about treatment, it can
also be important in assessing breast cancer risk for an
affected woman’s relatives. In this paper, we look at the
extent to which familial risk of breast cancer depends on
tumour morphology, an issue of both clinical and aetiolo-
gical significance.
Female relatives of women with breast cancer are at
increased risk of the disease, and it is well-established
that the magnitude of their risk depends upon the close-
ness of their relationship to their affected relatives and
the number and age at diagnosis of their affected relatives
[1-6]. The risk of breast cancer is substantially elevated
for women with an affected first-degree relative carrying
a high-risk mutation in BRCA1 or BRCA2 [4-6] or a
mutation in ATM [7] or TP53 [8-10], but high-risk muta-
tions in these susceptibility genes are rare and explain
only approximately 25% of the familial risk of breast
cancer [11].
We recently showed that two breast tumour morphol-
ogy features, trabecular growth pattern and high mitotic
index, were sufficient to identify almost all BRCA1 muta-
tion carriers in our population-based sample of breast
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cancer cases diagnosed before the age of 40 years [12]. We
also found that having five or more of nine pre-specified
tumour morphology features defined a morphological pro-
file that contained 27 (93%) of the 29 known BRCA1
mutation carriers [12], and of the 52 with this morphologi-
cal profile who were not found to carry a germline BRCA1
mutation, 16 (31%) were found to have methylation of the
BRCA1 promoter region in DNA from peripheral blood
[13].
Given the importance of tumour morphology features
to inform treatment choices and to identify BRCA1
mutation carriers [12] or BRCA1 promoter methylation
[13], we are now interested in identifying tumour mor-
phology features that predict familial risk of early-onset
breast cancer.
Methods
Australian Breast Cancer Family Registry
This study used data and materials from the Australian
Breast Cancer Family Registry (ABCFR), which includes a
population-based case-control-family study that has been
described in detail elsewhere [3,14-16]. Briefly, between
1992 and 1998, index cases were identified using state
population-based cancer registries as adult women living
in the metropolitan areas of Melbourne and Sydney, who
were aged less than 60 years when diagnosed with a his-
tologically confirmed first primary invasive breast cancer.
Index cases and participating relatives completed an
interviewer-administered risk factor questionnaire and a
family history questionnaire that asked for details of any
cancer history for themselves and for their first-degree
and second-degree relatives [3].
Missing family history data were imputed using a pre-
viously developed protocol for the following data items:
date of birth, age, vital status, date of death, age at death,
date at breast cancer diagnosis and age at breast cancer
diagnosis [3,6]. Verification of reported cancers through
cancer registries, medical records and death certificates
was obtained where possible [3].
Approval for the study was obtained from the Human
Research Ethics Committees of the University of Mel-
bourne and the Cancer Councils of Victoria and New
South Wales. All participants provided written informed
consent prior to participation in the ABCFR.
Tumour morphology review
Archival tumour blocks were sought for all index cases
under the age of 40 years at diagnosis [12], and a vali-
dated tumour morphology review was completed by
pathologists blinded to the mutation status of the index
case [17,18]. Briefly, the tumours were typed into primary
pattern and secondary pattern using the World Health
Organisation breast carcinoma classification with minor
modifications as described by Page et al. [19]. Tumour
grade was scored using the modified system of Bloom
and Richardson by assessing mitotic rate, tubular differ-
entiation and nuclear pleomorphism [19] as applied in
Southey et al. [12]. Sclerosis was defined as a central area
of fibrosis composed of fibroblasts and/or collagen that is
devoid of tumour cells, and labelled extensive if it com-
prised more than 20% of the tumour volume.
Estrogen receptor (ER) and progesterone receptor (PR)
status was obtained either from immunohistochemical
testing of tumour tissue [20] or from histopathology
reports held by the cancer registry or a diagnostic
laboratory [21].
From the tumour morphology review, the following
features were extracted as either absent or present:
Number of mitoses >50 (per 10 high powered fields)
Nuclear grade - malignant (scored as bland, inter-
mediate, malignant)
Tubule formation <10 (scored as >75, 10 to 75, <10)
Syncytical pattern ≥75% (scored as no, yes)
Circumscribed (scored as no, yes)
Pushing margins >50% (scored as no, yes)
Lymphocytic Infiltrate I - diffuse (scored as absent/
minimal, border, diffuse)
Lymphocytic infiltrate II - intense (scored as absent/
minimal, moderate, intense)
Glandular growth pattern (primary growth pattern)
Lobular growth pattern (primary or secondary
growth pattern)
Trabecular growth pattern (primary or secondary
growth pattern)
Tubular growth pattern (primary or secondary
growth pattern)
Acinar growth pattern (secondary growth pattern)
Sclerosis - extensive (scored as minimal, extensive)
Extensive intraductal carcinoma - present (scored as
absent, present, uncertain)
Necrosis - present (scored as absent, present,
uncertain)
Apoptosis - moderate or intense (scored as absent/
minimal, moderate, intense)
Lymphatic invasion - present (scored as absent, pre-
sent, uncertain)
Note: growth patterns were scored as glandular (pri-
mary only), lobular, trabecular, tubular and acinar
(secondary only).
Mutation testing for high-risk breast cancer genes
Testing for high-risk mutations in breast cancer predis-
position genes was conducted for all index cases under
the age of 40 years at diagnosis and from whom a blood
sample had been obtained. Full details of the BRCA1 and
BRCA2 mutation testing have been reported elsewhere
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and included: sequencing, protein truncation testing,
two-dimensional gel electrophoresis, screening for large
genomic alterations, testing for Ashkenazi founder muta-
tions and testing for duplication of exon 13 of BRCA1
[3,12]. ATM was tested for the c.7271 T>G mutation
[22-25] and testing for mutations in TP53 was performed
by Sanger sequencing and specific screening for larger
gene rearrangements [10].
BRCA1 methylation
Testing for methylation of the promoter region of
BRCA1 was conducted for all index cases under the age
of 40 years at diagnosis and for whom a pathology
review had been conducted [13].
Relatives
For the present study, mothers and sisters were included
if their index case was under the age of 40 years when
diagnosed with a histologically confirmed first primary
invasive breast cancer and had a pathology review com-
pleted. For each relative included in the analyses, the fol-
lowing data were extracted: relationship to the index
case; date of birth; vital status; age at interview or death;
breast cancer status; and age at diagnosis, if affected.
Statistical methods
Australian population-based female breast cancer inci-
dence rates, specific for age and year of birth (both in five-
year groupings), were obtained for 1983 to 2001 and extra-
polated to earlier years as described previously [6]. The
standardised incidence ratio (SIR) was estimated by com-
paring the observed number of mothers and sisters with
breast cancer with the number expected from applying
Australian population-based female breast cancer inci-
dence rates specific for age and year of birth (both in five-
year groupings). The ratio of SIRs and 95% confidence
intervals (CI) were calculated using the method described
by Breslow and Day [[26], pages 94-95]. Estimates of
hazard ratios (HR) were obtained from Cox proportional
hazards models and robust estimates of standard errors
were obtained to account for clustering within families.
We used the likelihood ratio test to identify best fitting
models by forward selection and confirmed by backwards
elimination, with a nominal P-value of 0.05 as a threshold,
and to test the null hypothesis that there is no association
between a set of predictive features and risks for relatives.
Multivariate linear regression models were also used
for estimating and testing associations between the mea-
sured pathology features and risk for relatives. These
models were fitted using Bayesian regularised regression
with the Least Absolute Shrinkage and Selection Opera-
tor (LASSO) penalty function [27,28]. The outcome vari-
able was the difference between expected and observed
SIRs, while the pathology features were used as binary
explanatory variables. To estimate the logistic regression
parameters, we generated 105 samples from the posterior
distribution of the parameters given the data, discarded
the first 2 × 104 samples as burnin, and accepted every
fifth posterior sample, thus reducing autocorrelation
within the chain.
Because many of the pathology features were highly
correlated, Bayesian LASSO regression and the Cox pro-
portional hazards model were used in tandem to select
features to be included in the multivariate model.
Statistical analyses were performed with Stata version
11, StataCorp LP, College Station, Texas, USA [29] and
MATLAB® version 7.13, MathWorks, Natick, Massa-
chusetts, USA [30]. All statistical tests were two-sided
and P-values <0.05 were considered nominally statisti-
cally significant.
Results
A total of 856 index cases diagnosed with a first primary
invasive breast cancer before the age of 40 years was
recruited, of whom 452 had a tumour morphology review
using archived tissue. Of these, 77 (17%) had either a
high-risk mutation in a breast cancer susceptibility gene
or methylation of the promoter region of BRCA1 in per-
ipheral blood DNA (31 BRCA1, 16 BRCA2, 1 ATM, 4
TP53, 25 BRCA1 promoter region methylation). The
remaining 375 (83%) constituted the subgroup for further
analyses. Table 1 shows the distribution of each tumour
morphology feature for all the 452 index cases and for
the 375 index cases in the subgroup. ER and PR status
was available for 401 (89%) of all index cases and for 329
(89%) of the subgroup of index cases.
There were 1,041 relatives (452 mothers and 589 sis-
ters) of the index cases, an average of 2.3 relatives per
index case, with a total of 11,786 person-years of observa-
tion (6,340 person-years for mothers and 5,446 person-
years for sisters). Data were imputed for relatives with
missing data as follows: seven dates of birth; six vital sta-
tus; four dates and ages at death; and one date and age at
breast cancer diagnosis.
Overall, 106 breast cancers were observed for the
mothers and sisters of the index cases while 36.56 were
expected from population incidence rates. The ratio of
observed to expected, the SIR, was 2.90 with a 95% CI
from 2.40 to 3.51.
Table 2 shows, for the presence and absence of each
of the pathology features, the number of observed and
expected cases of breast cancer, the SIR and 95% CI.
Table 2 also shows the ratio of SIRs and corresponding
95% CI and the P-values as a test of the difference
between the SIRs for the presence and absence of each
pathology feature. The test of the null hypothesis of no
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association with these variables and risks for relatives
was rejected (Χ18
2 = 106; P = 10-14). After fitting the
five significant morphology features, there was still sig-
nificant variation in risks for relatives across the remain-
ing 13 features (Χ13
2 = 30; P = 0.004).
Breast cancer risks for female first-degree relatives
were increased if the index cases’ tumours: were circum-
scribed; had pushing margins >50%; had intense lym-
phocytic infiltrate II; had number of mitoses >50; had a
trabecular growth pattern; had extensive intraductal car-
cinoma; had a syncytial pattern; did not have extensive
sclerosis; did not have a glandular growth pattern; or
were ER or PR negative (all P <0.04).
Table 3 shows the HR, 95% CI and P-values for the mul-
tivariate model. When all features were considered
together, the risks for relatives could be described by six
predictive features: absence of extensive sclerosis;; acinar
growth pattern; trabecular growth pattern; glandular
growth pattern; lobular growth pattern; and extensive
intraductal carcinoma (all P <0.02). When these factors
were included in the model, there was at best marginally
significant evidence for associations with tubular growth
pattern (HR = 0.51; 95% CI 0.28 to 0.93; P = 0.03) and
tubule formation (HR = 1.64; 95% CI 0.97 to 2.78; P =
0.07). Neither ER status nor PR status provided additional
(i.e. independent) information on breast cancer risk for
relatives (both P >0.3).
Subgroup analyses
When restricted to the subgroup of 375 index cases,
there were 876 relatives (375 mothers and 501 sisters),
an average of 2.3 relatives per index case, with a total of
9,954 person-years of observation (5,287 person-years
for mothers and 4,667 person-years for sisters). Overall,
69 breast cancers were observed and 30.74 were
expected based on population incidence rates; the SIR
was 2.25 with a 95% CI from 1.77 to 2.84.
Table 4 shows SIR and 95% CI and the ratio of the
SIRs for each of the pathology features. Breast cancer
risks for relatives were increased if the tumours: were
circumscribed; had pushing margins; had extensive
intraductal carcinoma; had glandular growth pattern; or
did not have extensive sclerosis (all P <0.04). Neither ER
status nor PR status provided independent information
on breast cancer risk for relatives (both P >0.4). The
test of the null hypothesis of no association with these
variables and risks for relatives was rejected (Χ18
2 =
71.0; P = 10-8). Even after fitting the four significant
morphology features there was still significant variation
in risks for relatives across the remaining 13 features
(Χ14
2 = 45.4; P = 0.0001).
Table 5 shows the HR, 95% CI and P-values for the
multivariate model. When all features were considered
together, the pathology features identified by the Baye-
sian LASSO regression and the Cox proportional
hazards models were: being circumscribed; having
extensive intraductal carcinoma; having lobular growth
pattern; and not having extensive sclerosis (all P <0.02).
When these factors were included in the model, no
other factors were even marginally associated.
Figure 1 shows that, based on the model presented in
Table 5, it would be predicted that women with breast
cancer diagnosed before age 40 years who do not have a
currently identifiable genetic risk, can be divided into
three groups defined by the four pathology features.
Relatives of the 128 (34%) index cases with none of
these features are predicted to be at no increased risk
(SIR = 1.03, 95% CI = 0.57 to 1.85) while relatives of the
37 (10%) cases who had two or more features were pre-
dicted to be at highest risk (SIR = 5.18, 95% CI = 3.22
to 8.33). The remaining 210 (56%) cases are predicted to
be at about average increased risk (SIR = 2.45, 95% CI =
1.80 to 3.33).
Figure 2 shows that some of the morphological and
immunohistochemical features are strongly associated
with one another, for both all index cases and for the
subgroup of index cases; cf. Figure 2 of [12]. For exam-
ple, notice that syncytial pattern and pushing margins
Table 1 Number and percentage of index cases with each





N = 452† % N = 375‡ %
Number of mitoses >50 71 15.7 33 8.8
Nuclear grade - malignant 386 85.4 316 84.3
Tubule formation <10 344 76.1 283 75.5
Syncytial pattern ≥75% 36 8.0 21 5.6
Circumscribed 93 20.6 56 14.9
Pushing margins 16 3.5 11 2.9
Lymphocytic infiltrate I - diffuse 162 35.8 136 36.3
Lymphocytic infiltrate II - intense 96 21.2 69 18.4
Glandular growth pattern 307 67.9 272 75.5
Lobular growth pattern 162 35.8 147 39.2
Trabecular growth pattern 109 24.1 65 17.3
Tubular growth pattern 74 16.4 64 17.1
Acinar growth pattern 87 19.3 60 16.0
Sclerosis - extensive 420 92.9 356 94.9
Extensive intraductal carcinoma 70 15.5 63 16.8
Necrosis 173 38.3 126 33.6
Apoptosis - moderate or intense 362 80.1 294 78.4
Lymphatic invasion 141 31.2 117 31.2
ER positive 226 56.4 201 61.1
PR positive 258 64.3 219 66.6
† ER and PR status was available for 401 index cases.
‡ ER and PR status was available for 329 index cases.
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are highly associated with each other and several other
features for both groups.
Discussion
For women with early-onset breast cancer who neither
carry a mutation in a known breast cancer susceptibility
gene nor have BRCA1 promoter region methylation in
peripheral blood DNA, features of their tumour mor-
phology predict wide variation in the risk of breast
Table 2 SIRs for mothers and sisters by tumour morphology features of the 452 index cases: the Australian Breast
Cancer Family Registry.
Feature Observed Expeceted SIR (95% CI) Ratio of SIRs (95% CI) P
Number of mitoses >50 Absent 81 31.70 2.56 (2.06 to 3.18) 2.01 (1.23 to 3.19) 0.002
Present 25 4.86 5.14 (3.47 to 7.61)
Nuclear grade - malignant Absent 13 5.32 2.44 (1.42 to 4.21) 1.22 (0.68 to 2.37) 0.5
Present 93 31.24 2.98 (2.43 to 3.65)
Tubule formation <10 Absent 21 9.18 2.29 (1.49 to 3.51) 1.36 (0.83 to 2.30) 0.2
Present 85 27.38 3.10 (2.51 to 3.84)
Syncytial pattern ≥75% Absent 92 34.20 2.69 (2.19 to 3.30) 2.21 (1.16 to 3.89) 0.01
Present 14 2.36 5.93 (3.51 to 10.01)
Circumscribed Absent 70 29.51 2.37 (1.88 to 3.00) 2.15 (1.40 to 3.26) <0.001
Present 36 7.05 5.11 (3.68 to 7.08)
Pushing margins Absent 96 35.40 2.71 (2.22 to 3.31) 3.15 (1.46 to 6.05) 0.001
Present 10 1.17 8.58 (4.62 to 15.95)
Lymphocytic infiltrate I - diffuse Absent 58 23.20 2.50 (1.93 to 3.23) 1.44 (0.96 to 2.14) 0.06
Present 48 13.36 3.59 (2.71 to 4.77)
Lymphocytic infiltrate II-intense Absent 73 29.83 2.45 (1.95 to 3.08) 2.00 (1.29 to 3.06) 0.001
Present 33 6.73 4.90 (3.49 to 6.90)
Glandular growth pattern Absent 47 10.80 4.35 (3.27 to 5.79) 0.53 (0.35 to 0.79) 0.001
Present 59 25.76 2.29 (1.77 to 2.96)
Lobular growth pattern Absent 62 22.80 2.72 (2.12 to 4.89) 1.18 (0.78 to 1.76) 0.4
Present 44 13.76 3.20 (2.38 to 4.30)
Trabecular growth pattern Absent 70 28.65 2.44 (1.93 to 3.09) 1.86 (1.21 to 2.82) 0.002
Present 36 7.91 4.55 (3.28 to 6.31)
Tubular growth pattern Absent 91 30.34 3.00 (2.44 to 3.68) 0.80 (0.43 to 1.39) 0.4
Present 15 6.23 2.41 (1.45 to 4.00)
Acinar growth pattern Absent 90 30.03 3.00 (2.44 to 3.68) 0.82 (0.45 to 1.40) 0.5
Present 16 6.53 2.45 (1.51 to 4.00)
Sclerosis - extensive Absent 20 2.36 8.46 (5.46 to 13.11) 0.30 (0.18 to 0.51) <0.001
Present 86 34.20 2.52 (2.04 to 3.11)
Extensive intraductal carcinoma Absent 81 30.74 2.34 (2.12 to 3.28) 1.63 (1.00 to 2.58) 0.03
Present 25 5.82 4.30 (2.90 to 6.36)
Necrosis Absent 64 23.93 2.67 (2.09 to 3.42) 1.24 (0.82 to 1.86) 0.3
Present 42 13.63 3.33 (2.46 to 4.50)
Apoptosis - moderate or intense Absent 16 7.30 2.19 (1.34 to 3.58) 1.40 (0.82 to 1.86) 0.2
Present 90 29.26 3.08 (2.50 to 3.78)
Lymphatic invasion Absent 75 24.96 3.01 (2.40 to 3.77) 0.89 (0.57 to 1.37) 0.6
Present 31 11.60 2.67 (1.88 to 3.80)
ER positive Absent 48 13.16 3.65 (2.75 to 4.84) 0.63 (0.41 to 0.96) 0.02
Present 46 20.16 2.28 (1.71 to 3.05)
PR positive Absent 42 11.32 3.71 (2.75 to 5.02) 0.66 (0.43 to 1.01) 0.04
Present 54 22.03 2.45 (1.88 to 3.20)
Table 3 Multivariate modelling of hazard ratios for
tumour morphology features of the index cases.
Feature Hazard Ratio (95% CI) P
Sclerosis - extensive 0.36 (0.20 to 0.65) 0.001
Acinar growth pattern 0.42 (0.22 to 0.78) 0.006
Glandular growth pattern 0.40 (0.25 to 0.65) <0.001
Extensive intraductal carcinoma 1.96 (1.28 to 3.00) 0.002
Circumscribed 1.85 (1.10 to 3.12) 0.02
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cancer for their first-degree female relatives, far more
than could be attributed to chance. For example, female
relatives of the approximately one-third of early-onset
breast cancer cases who had tumours that lacked any
morphological feature associated with familial risk were
at no increased risk of breast cancer. Female relatives of
the approximately one-sixth of early-onset breast cancer
Table 4 SIRs for mothers and sisters by morphology features of the subgroup of 375 index cases.
Feature Observed Expeceted SIR (95% CI) Ratio of SIRs (95% CI) P
Number of mitoses >50 Absent 60 28.50 2.11 (1.64 to 2.71) 1.91 (0.83 to 3.87) 0.07
Present 9 2.24 4.02 (2.09 to 7.73)
Nuclear grade - malignant Absent 10 4.67 2.14 (1.15 to 3.98) 1.06 (0.54 to 2.32) 0.9
Present 59 26.06 2.26 (1.75 to 2.92)
Tubule formation <10 Absent 16 7.86 2.04 (1.25 to 3.32) 1.14 (0.64 to 2.13) 0.7
Present 53 22.87 2.32 (1.77 to 3.03)
Syncytial pattern ≥75% Absent 64 29.42 2.18 (1.70 to 2.78) 1.75 (0.55 to 4.31) 0.2
Present 5 1.31 3.81 (1.58 to 9.14)
Circumscribed Absent 51 26.29 1.94 (1.47 to 2.55) 2.09 (1.15 to 3.63) 0.01
Present 18 4.45 4.04 (2.55 to 6.42)
Pushing margins Absent 66 29.98 2.10 (1.64 to 2.69) 3.76 (1.33 to 8.64) 0.002
Present 6 0.76 7.90 (3.55 to 17.59)
Lymphocytic infiltrate I - diffuse Absent 38 19.42 1.96 (1.42 to 2.69) 1.40 (0.84 to 2.31) 0.2
Present 31 11.32 2.74 (1.93 to 3.89)
Lymphocytic infiltrate II-intense Absent 53 25.89 2.05 (1.56 to 2.68) 1.61 (0.86 to 2.86) 0.1
Present 16 4.85 3.30 (2.02 to 5.39)
Glandular growth pattern Absent 25 7.58 3.30 (2.23 to 4.88) 0.58 (0.34 to 0.98) 0.03
Present 44 23.16 1.90 (1.41 to 2.55)
Lobular growth pattern Absent 36 18.34 1.96 (1.42 to 2.72) 1.36 (0.82 to 2.24) 0.2
Present 33 12.40 2.66 (1.89 to 3.74)
Trabecular growth pattern Absent 54 25.90 2.09 (1.60 to 2.72) 1.49 (0.78 to 2.67) 0.2
Present 15 4.84 3.10 (1.87 to 5.15)
Tubular growth pattern Absent 59 25.25 2.34 (1.81 to 3.02) 0.78 (0.36 to 1.54) 0.5
Present 10 5.49 1.82 (0.98 to 3.39)
Acinar growth pattern Absent 62 26.10 2.37 (1.85 to 3.04) 0.65 (0.25 to 1.42) 0.3
Present 7 4.56 1.54 (0.73 to 3.22)
Sclerosis - extensive Absent 8 1.45 5.52 (2.76 to 11.04) 0.38 (0.18 to 0.91) 0.01
Present 61 29.29 2.08 (1.62 to 2.68)
Extensive intraductal carcinoma Absent 51 25.61 1.99 (1.51 to 2.62) 1.77 (0.97 to 3.06) 0.04
Present 18 5.12 3.51 (2.21 to 5.58)
Necrosis Absent 48 21.35 2.25 (1.70 to 2.98) 0.99 (0.57 to 1.69) 1.0
Present 21 9.39 2.24 (1.46 to 3.43)
Apoptosis - moderate or intense Absent 12 6.64 1.81 (1.03 to 3.18) 1.31 (0.69 to 2.68) 0.4
Present 57 24.10 2.37 (1.83 to 3.07)
Lymphatic invasion Absent 53 21.10 2.51 (1.92 to 3.29) 0.76 (0.35 to 1.17) 0.1
Present 16 9.64 1.66 (1.02 to 2.71)
ER positive Absent 25 10.00 2.50 (1.69 to 3.70) 0.65 (0.44 to 1.33) 0.3
Present 34 17.85 1.91 (1.36 to 2.67)
PR positive Absent 26 9.10 2.86 (1.95 to 4.20) 0.70 (0.38 to 1.13) 0.1
Present 35 18.78 1.86 (1.34 to 2.60)
Table 5 Multivariate modelling of hazard ratios for
morphology features of the subgroup of 375 index cases.
Feature Hazard Ratio (95% CI) P
Sclerosis-extensive 0.30 (0.13 to 0.70) 0.005
Circumscribed 2.91 (1.39 to 6.10) 0.01
Extensive intraductal carcinoma 2.21 (1.25 to 3.90) 0.01
Lobular growth pattern 2.01 (1.10 to 3.70) 0.02
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cases who had tumours that had two or more of the
four features associated with familial risk were at a sub-
stantially increased risk of breast cancer. The latter find-
ing suggests there are undiscovered strong familial risk
factors for early-onset breast cancer. The former
suggests there is a substantial proportion of early-onset
breast cancer that does not have a familial, let alone
genetic, cause.
This work has built on previous work by us and
others that identified specific morphological features
Figure 1 SIRs (95% CIs) for mothers and sisters of 375 index cases by number of pathology features. Grey areas represent the proportion
of index cases with given number of features.
Figure 2 Associations between pathology features for all index cases (left) and the subgroup of cases (right). Each row and column
corresponds to a feature and the shading represents different levels of association, as measured by the odds ratios (ORs), as indicated. Odds
ratios <1 were assigned the same levels as their reciprocals.
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which predict cases with a germline BRCA1 mutation
[12,31,32]. We recently extended this to show that those
features also predict cases with methylation of the pro-
moter region of BRCA1 in peripheral blood DNA [13].
Here, we have widened the scope of what we are pre-
dicting to risks for relatives and, at the same time,
included all the other morphological features assessed
by a standardised and validated pathology review [18].
We also assessed morphological predictors both includ-
ing and excluding cases with a known genetic cause or
methylation of the BRCA1 promoter region.
When first considering all index cases, we found that
absence of extensive sclerosis, extensive intraductal carci-
noma, and trabecular and lobular growth patterns and
absence of acinar and glandular growth patterns were all
independent predictors of breast cancer for their first-
degree female relatives. When considered together, for
each of these six features their presence was associated
with an approximate doubling of risk for relatives. This
means there is a substantial gradient of risk for relatives
across a number of these features.
We have previously shown that the presence of trabe-
cular growth pattern was the major predictor of BRCA1
mutation status, as well as of methylation of the BRCA1
promoter region [12,13]. When we excluded index cases
with known genetic causes or methylation of the BRCA1
promoter region, absence of extensive sclerosis, circum-
scribed growth, extensive intraductal carcinoma and lob-
ular growth pattern were each independent predictors of
breast cancer risk for the first-degree female relatives of
the remaining index cases. Note from Figure 2 that these
factors are not highly associated with one another. Again,
the strengths of prediction were each an approximate
doubling or more of risk, and there was a substantial gra-
dient in risk for the relatives associated with the number
of these four features in the tumour of the index case.
Therefore, this study has identified characteristics of
breast cancers in young women, other than basal-like
carcinoma (which is likely rare in our subgroup analyses
due to exclusion of the index cases with either known
BRCA1 germline mutations or methylation of the BRCA1
promoter region), that are associated with increased risks
of breast cancer for first-degree relatives.
There are several strengths of our study. First, it is popu-
lation-based, so inference can readily be made at least to
the populations from which these index cases were
sampled, if not more generally. Second, because the index
cases were not selected on the basis of family history, this
study gives insights across the whole spectrum of index
cases. Third, we have used data from multiple pathologists
conducting a standardised and validated tumour review
and any systematic variation across the pathologists would
mean that our study has under-estimated the predictive
value of these morphology features.
The study also has some weaknesses. It is possible that,
despite extensive testing, some index cases carrying
mutations in BRCA1 and BRCA2 have not yet been iden-
tified, although this is likely to be, at most, a few percent
[3,6]. There may be some false positive statistical results
due to the vagaries of chance. The study has used only
early-onset index cases, so we cannot infer that the same
results will apply to index cases of later onset. Our index
cases were predominantly Caucasian and we cannot infer
that these results apply to other populations. Therefore,
there is a need for replication using independent samples,
and using samples of index cases with different ages at
onset and different ethnic backgrounds. Finally, although
we have identified a small number of features that inde-
pendently predict risks for relatives in our data set, there
was still substantial unexplained variation in risk. There-
fore, larger and pooled studies might identify a bigger
and better set of predictors. These might also clarify
which factors are the better independent predictors,
given that some features are highly associated with one
another (see Figure 2).
While there are several studies of breast cancer in rela-
tives as a function of the ER and PR tumour status of an
affected woman (for example, [33]), few have studied his-
tological features (for example, [34]). Several studies have
shown that stratification of breast tumours by ER and PR
status might be useful in partitioning breast cancer
families into more homogeneous subsets [35], but we have
found that these traditional immunohistochemical features
are not as important as morphological features for predict-
ing BRCA1 mutation carriers [12] or, as in this study, pre-
dicting breast cancer risks for relatives. Specific
morphological types of breast cancer might be associated
with familial cancers in general (or example, [36]).
Being able to quantify a woman’s risk of breast cancer is
important for genetic counselling, prevention and screen-
ing, as well as for aetiological research. Currently, risk esti-
mates associated with having a family history are based on
the age at diagnosis of cancer, not on the cancer’s mor-
phological features. We have shown here that, at least for
first-degree relatives of women with early-onset breast
cancer, this is likely leading to a misassignment of familial
risks for about one-half of index cases, being too high for
one-third and too low for one-sixth, by factors of two-fold
or more. Assignment of women with a family history of
breast cancer to different screening strategies based on
their absolute risk could be substantially improved were
the morphology features of the tumours of the relatives
taken into account. The role of morphological features to
predict BRAC1 mutation status has been established for
some time [31]. For early-onset breast cancer, we showed
that only two key features could better predict BRCA1
mutation carriers than family history and/or ER and PR
tumour status [12]. Now we have shown that just four
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other morphological features predict familial risks after
excluding the known breast susceptibility genes, and again
better than ER and PR tumour status.
It is highly relevant to genetic research and counselling
that one-third of early-onset breast cancers might not
even have a heritable genetic basis, as evidenced by our
observation that, for the group of index cases with none of
the four predictive features, their relatives were not at
increased risk. Most linkage studies and the recent gen-
ome-wide association studies have generally pooled all
cases when trying to find predisposing genes. It is also of
relevance to know if the type of breast cancers, as defined
by the morphology features identified here, ‘runs in the
family’, as this would greatly assist efforts at susceptibility
gene discovery.
For the affected women, their germline status, as well as
changes (both somatic genetic and epigenetic) to tumour
DNA, might influence gene expression that manifests in
nuances of cell growth and neoplastic tissue organisation
that are able to be observed by microscope. For example,
breast tumours arising in women with germline BRCA1
mutations and TP53 mutations have characteristic mor-
phology and acquired genetic and epigenetic mutation
profiles [37-39]. For unaffected relatives, any familial risk
associated with the breast tumour morphology features of
an affected relative must be related to similar genetic or
epigenetic variants that increase cancer susceptibility.
From this, it follows that DNA from affected women
whose breast tumour morphology features are associated
with the highest familial risks should be prioritised for
comprehensive genetic and epigenetic screening as they
provide the best prospect for the discovery of novel var-
iants that are associated with risk.
On their own, the ER and PR status of the index cases
were both associated with risk for relatives overall, with
about a 50% increased risk if the tumour of the index case
was negative for either of these immunohistochemical
markers. After the exclusions, the associations were of the
same magnitude and direction but no longer statistically
significant. However, neither of these immunohistochem-
ical markers were independent predictors of risks for rela-
tives once the more strongly predictive morphological
features were taken into account. That is, we present here
an advance on using ER and PR alone to assess the role of
pathology in predicting increased familial and possibly
genetic risks.
Conclusions
We have shown that relatively standard tumour mor-
phology can help unravel the complex heterogeneity of
breast cancers from the perspective of familial and
genetic risk, at least in the setting of early-onset disease.
There is a very wide variation in risks for relatives based
on tumour characteristics and this could not only be of
clinical value but might help discover new breast cancer
susceptibility genes.
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